Skip to main content
SpringerLink
Log in

Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Borderline personality disorder is a pervasive pattern of instability of interpersonal relationships, affects and self-image, as well as marked impulsivity. Although psychotherapy is needed to attain lasting improvements in a patient’s personality and overall functioning, practice guidelines state that pharmacotherapy is indicated to manage state symptoms and trait vulnerabilities. Three psychopathological dimensions are the main targets for pharmacotherapy of borderline personality disorder: affective dysregulation, impulsive-behavioural dyscontrol and cognitive-perceptual symptoms. Guidelines recommend the use of antidepressant agents and mood stabilizers for affective dysregulation and impulsivebehavioural dyscontrol, and antipsychotics for cognitive-perceptual symptoms.

This review aims to report and discuss data from clinical trials, reviews and meta-analyses concerning drug efficacy and tolerability in the treatment of borderline personality disorder. Investigations that considered antidepressant agents mainly focused on SSRIs, which are recommended as first-line treatments for affective instability and impulse dyscontrol. Both open-label and randomized controlled studies have been performed, predominantly concerning the efficacy of fluoxetine and fluvoxamine. Other classes of antidepressants, such as TCAs and MAOIs, were investigated as alternative treatments for borderline personality disorder, but the risk of adverse effects and toxicity is a limitation to their use in clinical practice. Increasing amounts of data have recently been collected on the use of mood stabilizers to control mood instability and impulsivity in patients with borderline personality disorder. More substantial data were derived from controlled trials of valproate semisodium, although other drugs such as lithium, carbamazepine, oxcarbazepine and lamotrigine were tested with promising results. Several first-generation antipsychotics were studied in open-label and controlled trials, with good effects on behavioural dyscontrol and psychotic-like symptoms. Selection biases and heterogeneity of drugs and methods somewhat limited the value of these results. More recent investigations have examined atypical antipsychotics, with most of these studies being open-label trials with small sample sizes; however, a few controlled studies have been performed using olanzapine, showing improvements in impulsivity, anger and hostility.

In conclusion, a large number of different drugs have been evaluated in the treatment of patients with borderline personality disorder. Initial findings are encouraging for many of these drugs. However, data need to be replicated in further controlled studies with head-to-head comparisons and long-term follow-ups. Many questions remain to be answered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000

    Google Scholar 

  2. Clarkin JF, Yeomans FE, Kernberg OF. Psychotherapy for borderline patients. New York: John Wiley & Sons, 1999

    Google Scholar 

  3. Livesley WJ. A practical approach to the treatment of patients with borderline personality disorder. Psychiatr Clin North Am 2000; 23: 211–32

    Article  PubMed  CAS  Google Scholar 

  4. American Psychiatric Association. Practice guidelines for the treatment of patients with borderline personality disorder. Washington, DC: American Psychiatric Association, 2001

    Google Scholar 

  5. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991; 148: 1647–58

    PubMed  CAS  Google Scholar 

  6. Siever LJ, Trestman R. The serotonin system and aggressive personality disorder. Int Clin Psychopharmacol 1993; 8: 33–9

    Article  PubMed  Google Scholar 

  7. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcipromine. Arch Gen Psychiatry 1988; 45: 111–9

    Article  PubMed  CAS  Google Scholar 

  8. Parsons B, Quitkin FM, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25: 524–34

    PubMed  CAS  Google Scholar 

  9. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50(5): 377–85

    Article  PubMed  CAS  Google Scholar 

  10. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238–46

    Article  PubMed  CAS  Google Scholar 

  11. Links P, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Personal Disord 1990; 4: 173–81

    Article  Google Scholar 

  12. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behaviour in personality disordered subjects. Arch Gen Psychiatry 1997; 54: 1081–8

    Article  PubMed  CAS  Google Scholar 

  13. Markovitz P. Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander E, Stein DJ, editors. Impulsivity and aggression. New York: John Wiley & Sons, 1995: 263–87

    Google Scholar 

  14. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23–9

    Article  PubMed  CAS  Google Scholar 

  15. Rinne T, de Kloet ER, Wouters L, et al. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002; 52: 1102–12

    Article  PubMed  CAS  Google Scholar 

  16. Cornelius JR, Soloff PH, George A, et al. Haloperidol vs phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 1993; 29(2): 333–7

    PubMed  CAS  Google Scholar 

  17. Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993; 34(3): 146–51

    Article  PubMed  CAS  Google Scholar 

  18. Shader RI, DiMascio A. Psychotropic drug side effects. Baltimore (MD): Williams and Wilkins, 1970

    Google Scholar 

  19. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691–7

    Article  PubMed  CAS  Google Scholar 

  20. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982; 139: 741–6

    PubMed  CAS  Google Scholar 

  21. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989; 155: 52–62

    Google Scholar 

  22. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46: 587–99

    Article  PubMed  CAS  Google Scholar 

  23. Oquendo MA, Mann JJ. The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 23: 11–25

    Article  PubMed  CAS  Google Scholar 

  24. Soloff PH, Meltzer CC, Becker C, et al. Impulsivity and prefrontal hipometabolism in borderline personality disorder. Psychiatry Res 2003; 123: 153–63

    Article  PubMed  CAS  Google Scholar 

  25. Frankle WG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [HC]McN 5652. Am J Psychiatry 2005; 162(5): 915–23

    Article  PubMed  Google Scholar 

  26. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62: 195–214

    PubMed  CAS  Google Scholar 

  27. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23: 169–92

    Article  PubMed  CAS  Google Scholar 

  28. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 885–93

    Article  PubMed  CAS  Google Scholar 

  29. Coccaro EF, Astill JL, Herbert JL, et al. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol 1990; 10: 373–5

    Article  PubMed  CAS  Google Scholar 

  30. Cornelius JR, Soloff PH, Perel JM, et al. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26: 151–4

    PubMed  CAS  Google Scholar 

  31. Cornelius J, Soloff PH, Perel J, et al. A preliminary trial of fluoxetine in refractory borderline patients. J Clin Psychopharmacol 1991; 11: 116–20

    Article  PubMed  CAS  Google Scholar 

  32. Markovitz PJ, Calabrese JR, Charles SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064–7

    PubMed  CAS  Google Scholar 

  33. Teicher MH, Glod CA, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–10

    PubMed  CAS  Google Scholar 

  34. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137–41

    PubMed  CAS  Google Scholar 

  35. Silva H, Jerez S, Paredes A, et al. Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25(6): 391–5

    PubMed  CAS  Google Scholar 

  36. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004 Mar; 65(3): 379–85

    Article  PubMed  CAS  Google Scholar 

  37. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903–7

    Article  PubMed  CAS  Google Scholar 

  38. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd. ed., revised. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  39. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58(1): 19–36

    Article  PubMed  CAS  Google Scholar 

  40. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006; 60(4): 482–91

    Article  PubMed  CAS  Google Scholar 

  41. Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996; 16: 32–47S

    Article  Google Scholar 

  42. Keck Jr PE, McElroy SL, Richt N, et al. What makes a drug a primary mood stabilizer? Mol Psychiatry 2002; 7Suppl. 1: S8–14

    Article  PubMed  CAS  Google Scholar 

  43. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146–51

    Article  PubMed  Google Scholar 

  44. Grof P. Mood-stabilizers: the archeology of the concept [commentary]. Bipolar Disord 2003; 5: 453–5

    Article  PubMed  Google Scholar 

  45. Harris M, Chandran S, Chakraborty N, et al. Mood stabilizers: the archeology of the concept. Bipolar Disord 2003; 5: 446–52

    Article  PubMed  Google Scholar 

  46. Keck Jr PE, McElroy SL. Redefining mood stabilization. J Affect Disord 2003; 73: 163–9

    Article  PubMed  Google Scholar 

  47. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol 2005; 20: 225–36

    Article  PubMed  CAS  Google Scholar 

  48. Mackinnon DF, Pies R. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord 2006; 8: 1–14

    Article  PubMed  CAS  Google Scholar 

  49. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519–22

    PubMed  CAS  Google Scholar 

  50. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199–203

    Article  PubMed  CAS  Google Scholar 

  51. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621–4

    Article  PubMed  Google Scholar 

  52. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442–6

    Article  PubMed  CAS  Google Scholar 

  53. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287–91

    Article  PubMed  CAS  Google Scholar 

  54. Zanarini MC, Frankenburg FR, Gunderson JG. Pharmacotherapy of borderline outpatients. Compr Psychiatry 1988; 29: 372–8

    Article  PubMed  CAS  Google Scholar 

  55. Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull 1989; 25: 515–23

    PubMed  CAS  Google Scholar 

  56. Goldberg SC. Prediction of change in borderline personality disorder. Psychopharmacol Bull 1989; 25: 550–5

    PubMed  CAS  Google Scholar 

  57. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117–28

    Article  PubMed  CAS  Google Scholar 

  58. Stein DJ. Drug treatment of the personality disorders. Br J Psychiatry 1992; 161: 167–84

    Article  PubMed  CAS  Google Scholar 

  59. Delva NJ, Hawken ER. Preventing lithium intoxication: guide for physicians. Can Fam Physician 2001; 47: 1595–600

    PubMed  CAS  Google Scholar 

  60. Fagiolini A, Kupfer DJ, Scott J, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psychiatr Soc 2006; 15(2): 123–7

    Google Scholar 

  61. Van Gerven HA, Boer WH. Chronic renal function disorders during lithium use. Ned Tijdschr Geneeskd 2006; 150(31): 1715–8

    PubMed  Google Scholar 

  62. Tang SW. Using lithium [letter]. Hong Kong Med J 2006; 12(4): 253

    PubMed  CAS  Google Scholar 

  63. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Prim Psychiatry 2002; 9: 55–9

    Google Scholar 

  64. Denicoff KD, Meglathery SB, Post RM, et al. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry 1994; 55: 70–6

    PubMed  CAS  Google Scholar 

  65. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52: 13–9

    Article  PubMed  CAS  Google Scholar 

  66. Mattes J. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry Clin Neurosci 1990; 2: 159–64

    PubMed  CAS  Google Scholar 

  67. Kravitz HM, Fawcett J. Carbamazepine in the treatment of affective disorders. Med Sci Res 1987; 15: 1–8

    Google Scholar 

  68. Blumer D, Heibronn M, Himmelhoch J. Indications for carbamazepine in mental illness: atypical psychiatric disorder or temporal lobe syndrome? Compr Psychiatry 1988; 29: 108–22

    Article  PubMed  CAS  Google Scholar 

  69. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24(1): 91–103

    Article  PubMed  CAS  Google Scholar 

  70. Zubcevic S, Gavranovic M, Katica V, et al. Efficacy and tolerability of carbamazepine as the initial drug used in the treatment of epilepsy. Med Arch 2002; 56(3 Suppl. 1): 26–9

    Google Scholar 

  71. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5Suppl. 1: 83–8

    Google Scholar 

  72. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002; 72Suppl. 1: S23–34

    Article  PubMed  CAS  Google Scholar 

  73. Hummel B, Waiden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002; 4: 412–7

    Article  PubMed  CAS  Google Scholar 

  74. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in the treatment of affective and schizoaffective disorders. Fortschr Neurol Psychiatr 2003; 71: 255–64

    Article  PubMed  CAS  Google Scholar 

  75. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003; 64Suppl. 8: 9–14

    PubMed  CAS  Google Scholar 

  76. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003; 64: 943–5

    Article  PubMed  CAS  Google Scholar 

  77. Perugi G, Toni C, Frare F, et al. An open case study in Italy of oxcarbazepine, an effective mood stabilizer, in patients with drug resistant/intolerant bipolar I disorders [poster]. XVI Congress of European College of Neuropsychopharmacology; 2003 Sep 20–24; Prague

  78. Raja M, Azzoni A. Oxcarbazepine versus valproate in mood and schizoaffective disorders. Int J Neuropsychopharm 2003; 6: 409–14

    Article  CAS  Google Scholar 

  79. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004; 79: 273–7

    Article  PubMed  CAS  Google Scholar 

  80. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57–75

    PubMed  Google Scholar 

  81. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, ad oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry 2004; 65: 738–9

    Article  PubMed  Google Scholar 

  82. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004; 65Suppl. 10: 28–35

    PubMed  CAS  Google Scholar 

  83. Gentry JR, Hill C, Malcolm R. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry 2002; 14: 233–45

    PubMed  Google Scholar 

  84. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia. Am J Psychiatry 2004; 161: 1130–1

    Article  PubMed  Google Scholar 

  85. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111–5

    Article  PubMed  CAS  Google Scholar 

  86. Martinez W, Ingenito A, Blakeslee M, et al. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006; 9(3): 448–56

    Article  PubMed  Google Scholar 

  87. McAuley JW, Biederman TS, Smith JC, et al. Newer therapies in the drug treatment of epilepsy. Ann Pharmacother 2002; 36(1): 119–29

    Article  PubMed  CAS  Google Scholar 

  88. Pol P. Enhancement of GABAergic inhibition: a mechanism of action of benzodiazepines, phenobarbital, valproate and L-cycloserine in the cat spinal cord. Electroencephalogr Clin Neurophysiol 1982; 36 Suppl.: 188–98

    Google Scholar 

  89. Wilcox JA. Divalproex sodium in the treatment of aggressive behaviour. Ann Clin Psychiatry 1994; 6: 17–20

    Article  PubMed  CAS  Google Scholar 

  90. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7: 33–7

    Article  PubMed  CAS  Google Scholar 

  91. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506–10

    PubMed  CAS  Google Scholar 

  92. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676–80

    Article  PubMed  CAS  Google Scholar 

  93. Landy SH, McGinnis J. Divalproex sodium: review of prophylactic migraine efficacy, safety and dosage, with recommendations. Tenn Med 1999; 92: 135–6

    PubMed  CAS  Google Scholar 

  94. Walia KS, Khan EA, Ko DH, et al. Side effects of antiepileptics: a review. Pain Pract 2004; 4(3): 194–203

    Article  PubMed  Google Scholar 

  95. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119–30

    Article  PubMed  CAS  Google Scholar 

  96. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51: 333–43

    Article  PubMed  CAS  Google Scholar 

  97. Green B. Lamotrigine in mood disorders. Curr Med Res Opin 2003; 19: 272–7

    Article  PubMed  CAS  Google Scholar 

  98. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 2004; 79: 297–303

    Article  PubMed  CAS  Google Scholar 

  99. Faught E, Matsuo FU, Schachter S, et al. Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav 2004; 5(1): 31–6

    Article  PubMed  Google Scholar 

  100. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271(12): 918–24

    CAS  Google Scholar 

  101. Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63(6): 1022–6

    Article  PubMed  CAS  Google Scholar 

  102. Teicher M, Glod C, Aaronson S, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989; 25: 535–49

    PubMed  CAS  Google Scholar 

  103. Kutcher S, Papatheodorou G, Reiter S, et al. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995; 20: 113–8

    PubMed  CAS  Google Scholar 

  104. Leone N. Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982; 43: 148–50

    PubMed  CAS  Google Scholar 

  105. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984; 141(11): 1455–8

    PubMed  CAS  Google Scholar 

  106. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorder treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680–6

    Article  PubMed  CAS  Google Scholar 

  107. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4(4): 291–8

    Article  PubMed  CAS  Google Scholar 

  108. Quieffin J, Brochet E, Gamerman G, et al. Ventricular arrhythmia following thioridazine poisoning. Ann Cardiol Angiol 1991; 40(4): 199–201

    CAS  Google Scholar 

  109. Lingjaerde O. Electrocardiographic changes, disturbances of cardiac rhythm, and sudden deaths during treatment with phenothiazine drugs. Tidsskr Nor Laegeforen 1967; 87(2): 90–4

    PubMed  CAS  Google Scholar 

  110. Jarema M, Sartorius N. Treatment of bipolar disorders with second generation antipsychotic medications. Neuro Endocrinol Lett 2005; 26Suppl. 1: 5–7

    Google Scholar 

  111. Malhi GS, Berk M, Bourin M, et al. Atypical mood stabilizers: a typical role for atypical antipsychotics. Acta Psychiatr Scand Suppl 2005; 111(426): 29–38

    Article  Google Scholar 

  112. Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. Aust N Z J Psychiatry 2005; 39: 652–61

    Article  PubMed  Google Scholar 

  113. Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord 2005; 7Suppl. 4: 21–33

    Article  PubMed  CAS  Google Scholar 

  114. Conus P, Berk M, McGorry PD. Pharmacological treatment in the early phase of bipolar disorders: what stage are we at? Aust N Z J Psychiatry 2006; 40: 199–207

    Article  PubMed  Google Scholar 

  115. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402–5

    Article  PubMed  CAS  Google Scholar 

  116. Benedetti F, Sforzini L, Colombo C, et al. Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103–7

    Article  PubMed  CAS  Google Scholar 

  117. Chengappa KN, Ebeling T, Kang JS, et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 1999; 60: 477–84

    Article  PubMed  CAS  Google Scholar 

  118. Kouzam HR, Donnelly NJ. Remission of selfmutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis 1997; 185: 348–9

    Article  Google Scholar 

  119. Szighethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol 1997; 17: 326–7

    Article  Google Scholar 

  120. Schulz SC, Camlin KL, Berry SA, et al. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429–35

    Article  PubMed  CAS  Google Scholar 

  121. Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psych Clin Neurosci 2001; 55: 161–2

    Article  CAS  Google Scholar 

  122. Rocca P, Marchiaro L, Cocuzza E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241–4

    Article  PubMed  CAS  Google Scholar 

  123. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849–54

    Article  PubMed  CAS  Google Scholar 

  124. Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104–9

    Article  PubMed  CAS  Google Scholar 

  125. Soler J, Pascual JC, Barrachina J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221–4

    Article  PubMed  Google Scholar 

  126. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163(5): 833–8

    Article  PubMed  Google Scholar 

  127. Bhana N, Foster RH, Olney R, et al. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61: 111–61

    Article  PubMed  CAS  Google Scholar 

  128. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997; 133: 323–8

    Article  PubMed  CAS  Google Scholar 

  129. Brecher M, Rak IW, Melvin K, et al. The longterm effect of quetiapine (‘Seroquel’) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–91

    Article  CAS  Google Scholar 

  130. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transient high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553–9

    Article  PubMed  CAS  Google Scholar 

  131. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry 2003; 4: 42–4

    Article  PubMed  Google Scholar 

  132. Adityanjee A, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002; 63Suppl. 13: 32–8

    PubMed  CAS  Google Scholar 

  133. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005; 66: 1298–303

    Article  PubMed  CAS  Google Scholar 

  134. Perrella C, Carrus D, Costa E, et al. Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 31(1): 158–63

    Article  PubMed  CAS  Google Scholar 

  135. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006; 67(7): 1042–6

    Article  PubMed  CAS  Google Scholar 

  136. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325–37

    Article  PubMed  CAS  Google Scholar 

  137. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90

    Article  PubMed  CAS  Google Scholar 

  138. Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004; 4Suppl. 2: 17–25

    Article  Google Scholar 

  139. Centorrino F, Fogarty KV, Cimbolli P, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2005; 11(4): 241–7

    Article  PubMed  Google Scholar 

  140. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6(12): 2091–101

    Article  PubMed  CAS  Google Scholar 

  141. Simon JS, Nemeroff CB. Aripiprazole augmentation for the treatment of partially responding and non responding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216–20

    Article  PubMed  CAS  Google Scholar 

  142. Patkar AA, Peindl K, Mago R, et al. An open-label, raterblinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8(2): 82–7

    Article  PubMed  Google Scholar 

  143. Mobascher A, Mobascher J, Schlemper V, et al. Aripiprazole pharmacotherapy of borderline personality disorder. Pharmacopsychiatry 2006; 39(3): 111–2

    Article  PubMed  CAS  Google Scholar 

  144. Nickel MK, Loew TH, Gil FP. Aripiprazole in the treatment of borderline patients: II. An 18-month follow-up. Psychopharmacology 2007; 191(4): 1023–6

    CAS  Google Scholar 

  145. Lambertenghi Deliliers G. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000; 85(3): 233–7

    PubMed  CAS  Google Scholar 

  146. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007; 13(1): 13–24

    Article  PubMed  Google Scholar 

  147. Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci 2007; 61(1): 54–8

    Article  PubMed  CAS  Google Scholar 

  148. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005; 28: 163–8

    Article  PubMed  CAS  Google Scholar 

  149. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307–25

    Article  PubMed  CAS  Google Scholar 

  150. Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Aripiprazole Study Group. Am J Psychiatry 2003; 160: 1651–8

    Google Scholar 

  151. Nosè M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2006; 21(6): 345–53

    Article  PubMed  Google Scholar 

  152. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 2006; (1): CD005653

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review. All persons who made substantial contributions to this review met the criteria for authorship.

Author information

Authors and Affiliations

  1. Unit of Psychiatry, Department of Neurosciences, Service for Personality Disorders, University of Turin, Via Cherasco 11, Turin, 10126, Italy

    Silvio Bellino, Erika Paradiso & Filippo Bogetto

Authors
  1. Silvio Bellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erika Paradiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Filippo Bogetto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvio Bellino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bellino, S., Paradiso, E. & Bogetto, F. Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. CNS Drugs 22, 671–692 (2008). https://doi.org/10.2165/00023210-200822080-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200822080-00005

Keywords

Search

Navigation